Get notified of page updates

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

Clinicaltrials.gov identifier:
NCT02849496

Study Contact Information:

For additional information, please contact: Jamison Langguth by phone at: 203-4647261 or by email.

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study 

This is a study for women or men who have been diagnosed with advanced breast cancer with a 1/2 mutation. The goal of this study is to look at whether giving the damage repair inhibitor ()  (Lynparza) in combination with the atezolizumab (Tecentriq) improves outcomes for patients compared to alone.  NOTE: This study is no longer enrolling people.

This Study is Open To:

NOTE: This study is no longer enrolling people.

This Study is NOT Open To:

NOTE: This study is no longer enrolling people.

Study Contact Information:

For additional information, please contact: Jamison Langguth by phone at: 203-4647261 or by email.

Clinicaltrials.gov identifier:
NCT02849496

Study Contact Information:

For additional information, please contact: Jamison Langguth by phone at: 203-4647261 or by email.

PRINTER FRIENDLY PAGE